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Abstract
Background: To describe long term outcomes of Mycobacterium avium complex (MAC) immune
reconstitution inflammatory syndrome (IRIS).
Methods: Cases of MAC IRIS were retrospectively identified at four HIV clinics (Michigan,
Maryland, Rhode Island, and Indiana) from 1996–2004. Patients were included if they were initially
diagnosed with AIDS and found to have evidence of focal MAC infection documented by tissue
culture or PCR after initiating HAART, and at least 6 months of follow up.
Results: Among the 20 patients included, the mean age was 40 years, mean CD4 cell count was
24/mm3 at pretreatment baseline and 100/mm3 at time of MAC IRIS diagnosis. Sites of disease
included lymph nodes (15 patients [8 peripheral, 8 abdominal and 1 peripheral and abdominal]),
gastrointestinal tract (7) and liver (3). Sixteen patients (80%) responded to treatment and were
disease free after a mean of 17.4 months of therapy for MAC IRIS; IRIS therapy was withdrawn in
6 without relapse. Four patients (non-responder group) had persistent or relapsing disease despite
27 months of ongoing MAC IRIS treatment. At the time of resolution or last follow-up, the mean
CD4 cell count and viral load was 143/mm3 and 7,000 c/mL for responders, and 65/mm3 and 17,000
c/mL for non-responders, respectively. Most patients with peripheral adenopathy were responders
(7/8; 88%); many with abdominal adenopathy (4/8; 50%) were nonresponders.
Conclusion: The majority of patients with MAC IRIS eventually responded to treatment. Our
sample size was not adequate to perform statistical analysis, but there was a tendency towards
adequate CD4 response to HAART and peripheral rather than intraabdominal adenopathy among
responders.
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Focal manifestations of Mycobacterium avium complex
(MAC) may occur in AIDS patients with severe immune
suppression after starting HAART [1,2]. This is thought to
be the result of specific cell mediated immune response to
MAC antigens associated with highly active antiretroviral
therapy (HAART). The syndrome, referred to as the
immune reconstitution inflammatory syndrome (IRIS),
most often occurs within 3 months of initiating HAART,
but may also occur years later. The development of IRIS
may reflect an unmasking of subclinical disease or wors-
ening of the intensity or alteration of the manifestations
of MAC infection that had been present prior to initiation
of HAART [3,4].
Studies have addressed the clinical features of IRIS at
onset, as well as the course of six patients after one year [5-
10] and 29 months of follow up [11]. Other reports have
described patients with refractory or relapsing MAC IRIS
disease [5,7,9,10]. Nonetheless, it remains unknown
whether the majority of patients with this syndrome will
eventually respond to specific treatment, and what fea-
tures may accompany successful response to therapy. We
undertook this study to better define the long-term out-
come of MAC IRIS.
Methods
Patients who received treatment at four university HIV/
AIDS programs in the United States (University of Michi-
gan, Ann Arbor, MI; Brown University, Providence, RI;
Johns Hopkins University, Baltimore, MD; Methodist
Hospital, Indianapolis, IN) were retrospectively identified
from 1998 to December 2004. One patient (#18) has
been previously reported elsewhere [10]. We used a previ-
ously described definition of IRIS for criteria for inclusion
[3]; specifically, patients were included if they were ini-
tially diagnosed with AIDS, were started on therapy with
HAART, and developed focal end organ (including lymph
node) MAC infection documented by culture of a nor-
mally sterile site or by PCR and histopathologic changes
of tissue inflammation. Time of diagnosis after starting
HAART was not used as criteria for inclusion as previously
published case definitions did not include this parameter.
Patients were included if they had been followed for at
least 6 months after initiation of treatment for MAC IRIS.
CD4 cell count and quantitative HIV viral load measure-
ment at baseline, as well after beginning HAART, were
recorded. Clinical information on site of MAC IRIS
involvement and treatment were abstracted from patient
records. Patients were categorized as responders if they
had clinical resolution and radiological improvement of
IRIS. Those who did not have evidence of resolution of
IRIS or had relapsing disease despite appropriate treat-
ment were deemed non-responders. Clinical and labora-
tory data were analyzed using calculation of means and
standard deviations. This study was approved by the Insti-
tutional Review Board of each participating center.
Results
Overall patient population
Table 1 outlines the clinical features of the twenty patients
with MAC IRIS that were identified (11 Michigan, 2
Rhode Island, 6 Maryland, 1 Indiana). Two additional
patients were excluded from analysis because they had
MAC isolated from only bone marrow in the absence of
other organ involvement. Seventeen patients were male;
12 were Caucasian, 7 African-American, and one His-
panic. Risk factors for the acquisition of HIV included
homosexual contact (10), heterosexual contact (4), injec-
tion drug use (4), occupational injury (1), and unknown
(1). The average age was 40 years (± 8.5, range 27 to 59).
Average total follow-up time was 3.8 years (range 6
months to 7 years). All patients were treated with HAART
regimens that contained at least 3 drugs, including either
a protease inhibitor or non-nucleoside reverse tran-
scriptase inhibitor with two nucleoside reverse tran-
scriptase inhibitors. The mean pre-HAART CD4 cell count
was 24 ± 45/mm3 which increased to 100 ± 85/mm3 at the
time of MAC IRIS diagnosis. In 6 patients (30%), HAART
was initiated after disseminated MAC was diagnosed
(mean time from MAC diagnosis to HAART initiation was
36 days ± 39). Seven of the 20 total patients had been
receiving MAC prophylaxis prior to the development of
MAC IRIS.
The median time from initiation of HAART to diagnosis of
MAC IRIS was 2.6 months (range 10 days to 4.7 years).
Seven (35%) patients developed IRIS less than 60 days
after initiation of HAART, 10 (50%) from 60 days to one
year, and 3 (15%) after more than a year. Presenting
symptoms of IRIS included fever (15 patients), abdomi-
nal pain (9), symptomatic lymphadenopathy (6), night
sweats (4), loose stools (4), nausea and vomiting (4),
fatigue, weight loss, and rash (1 each). The most common
focal site of IRIS was lymph nodes (15 patients [8 periph-
eral, 8 abdominal and 1 peripheral and abdominal]).
Other sites included: gastrointestinal tract (7 patients)
and liver (3). All patients in whom MAC was isolated
from cultures of bone marrow also had focal inflamma-
tion of another site (liver or gastrointestinal tract), reflect-
ing the case definition of IRIS. Other sites of MAC
isolation included liver biopsy (3 patients), and aspirates
or biopsies of other tissues. Isolator blood cultures were
positive in 2 patients who also had MAC isolated from a
focal site of inflammation (Table 1). One patient in
whom MAC was not isolated from cultures had a diagno-
sis of MAC confirmed by PCR of a lymph node specimen.
All patients received a macrolide (azithromycin or clari-
thromycin) and ethambutol for the treatment of MACPage 2 of 7
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agent. Four patients received ciprofloxacin and two
received amikacin as part of their regimen of treatment.
Eight patients received therapy with adjunctive agents: 8
received oral corticosteroids for an average of 17 ± 14.6
months, and 2 received granulocyte-colony stimulating
factor (G-CSF). Table 2 outlines the key clinical features of
each patient.
Responders
Sixteen of the 20 patients (80%) experienced clinical and/
or radiographic resolution of signs of active infection after
19.5 ± 21.7 months (range 22 days to 5.2 years) of MAC
IRIS treatment (patients 1–16 in Table 2). The mean pre-
HAART CD4 cell count in the responder group was 29/
mm3 and was 88/mm3 at the time of IRIS diagnosis (Table
3). The mean CD4 cell count was 143/mm3 at the time of
clinical resolution for the responder group (IRIS follow up
in Table 3). One of the patients in this group had a relapse
of infection one year after resolution of initial symptoms.
Peripheral lymph node was the most common site of
involvement in responders (7/16; 44%); of the eight
patients with peripheral lymph node involvement, seven
(88%) were responders. MAC IRIS treatment has been
withdrawn in 6 of the 16 responders without recurrence of
symptoms. Six patients from this group required adjunc-
tive corticosteroids for a mean of 12.8 ± 5.9 months. Two
cases of patients who responded successfully to treatment
of MAC IRIS are described in detail below (patients #2
and #3 from Table 2).
Patient #2 (Responder; resolution of intra-abdominal
MAC IRIS lymphadenitis following MAC IRIS therapy and
sustained immunologic recovery after the initiation of
HAART): A 40-year-old man initially diagnosed with
Pneumocystis pneumonia and HIV infection (CD4 cell
count 43/mm3, viral load 32,318 c/mL) initially
responded well to trimethoprim/sulfamethoxazole and
corticosteroids. He then developed recurrent fevers up to
102°F after beginning zidovudine, lamivudine, and efa-
virenz. An abdominal CT scan showed multiple enlarged
mesenteric, retroperitoneal and periaortic lymph nodes. A
lymph node core needle biopsy of an enlarged lymph
node showed necrotizing granulomas. Mycobacterium
Table 1: Summary of clinical parameters
Characteristic Responders N = 16 Non-responders N = 4
Age 40 38
Ethnicity:
Caucasian 8 3
African-American 7 1
Hispanic 1 0
Gender (male) 13 4
MAC prophylaxis 4 3
Prior disseminated MAC 4 4
Time to IRIS (mean) 248 days 195 days
IRIS site*:
Lymph node(s) 11 4
GI tract 5 2
Liver 3 0
IRIS therapy†:
2 drugs 8 2
3 drugs 6 0
4 or more drugs 2 2
Time to resolution or follow up (mean) 522 days 888 days
* Patients may have had more than one site of IRIS involvement.
†2 drugs – macrolide + ethambutol, 3 drugs – addition of rifabutin, 4 or more drugs – addition of amikacin, fluoroquinolone, or linezolid.
Table 2: Summary of immunologic and virologic parameters (expressed as means).
Baseline IRIS Diagnosis IRIS F/U*
CD4 VL CD4 VL CD4 VL
Responders (n = 18) 29 ± 50 422 K ± 502 K 88 ± 65 59 K ± 186 K 143 ± 109 7 K ± 23 K
Non-Responders (n = 4) 6 ± 4 259 K ± 185 K 152 ± 143 1 K ± 1 K 65 ± 53 17 K ± 35 K
*For responders, F/U = ResolutionPage 3 of 7
(page number not for citation purposes)
Jo
u
r
n
a
l
 
o
f
 
T
r
a
n
s
l
a
t
i
o
n
a
l
 
M
e
d
i
c
i
n
e
 
2
0
0
7
,
 
5
:
5
0
h
t
t
p
:
/
/
w
w
w
.
t
r
a
n
s
l
a
t
i
o
n
a
l
-
m
e
d
i
c
i
n
e
.
c
o
m
/
c
o
n
t
e
n
t
/
5
/
1
/
5
0
P
a
g
e
 
4
 
o
f
 
7
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 3: Summary of clinical and laboratory findings for Responders (1–16) and Non-responders (17–20).
CD4 count (cells/ml) Treatment
# Age, sex Symptoms Organ involvement Diagnostic procedure Baseline 
viral loada
Baselineb At time 
of IRIS
At time of 
follow upc
Viral load at 
follow up
Time to IRISd 
(days)
MAC therapy Duration of 
corticosteroid 
(months)
1 37, F Fever, N/V GI, liver Liver biopsy 249,880 10 54 84 <50 226 Azm, ETB 12
2 40, M Fever, abd pain Abd LN LN aspirate 32,318 43 165 229 <50 66 Azm, ETB ---
3 44, M Fever, abd pain GI, Bone marrow BMBx, blood Cx 215,201 69 199 326 <50 25 Clm, ETB, RIB, cipro 22
4 59, M Fever, abd pain GI, Bone marrow GI biopsy, BMBx 188,000 34 98 140 <50 604 Azm, ETB, RIB, cipro 10
5 33, M LAN Axillary LN LN aspirate 72,777 20 64 89 <50 1689 Clm, ETB ---
6 53, M LAN Axillary LN Tissue culture 750,000 9 111 201 <50 306 Clm, ETB ---
7 53, M Fever, rash, NS Supraclavicular LN LN aspirate 31,517 5 142 97 <50 192 Azm, ETB, RIB ---
8 47, M Fever, abd pain, NS Supraclavicular LN, Liver Liver biopsy 500,000 2 3 13 21,439 122 Azm, ETB, RIB Not available
9 32, M LAN Cervical LN LN aspirate 117,580 204 224 403 <50 456 Clm, ETB, RIB ---
10 28, M LAN Axillary LN Tissue culture 217,174 8 66 226 <50 75 Clm, ETB, RIB ---
11 38, M Fever, Wt loss Liver, Bone marrow Liver Bx, BMBx 750,000 4 35 99 87 10 Clm, ETB ---
12 38, M Fever, LAN, fatigue Cervical LN Tissue culture 366,000 16 46 10 97,000 18 Azm, ETB, RIB ---
13 40, M Fever, abd pain, N/V, 
diarrhea
Abd LN, GI LN aspirate 321,851 21 71 73 849 84 Azm, ETB 6
14 40, M Fever, diarrhea, cough ABD LN, Mediastinal LN Blood Cx, CT 624,697 1 18 48 <50 63 Clm, ETB, RIB 14
15 30, F Fever, NS, diarrhea GI, Bone marrow Tissue Bx, BMBx 205,115 9 39 141 336 16 Clm, ETB ---
16 42, F Fever, NS Abd LN Blood Cx, CT 2,115,623 7 65 118 2,729 17 Clm, ETB ---
17 46, M LAN, abd pain Abd LN, supraclavicular LN, 
mediastinal LN
LN aspirate 292,571 11 72 108 <50 359 Azm, ETB, RIB, cipro, 
amikacin
---
18 44, M Fever, abd pain Abd LN LN aspirate 205,000 5 61 40 <50 360 Clm, ETB, RIB, cipro, 
amikacin
48
19 27, M Fever, abd pain, N/V GI, abd LN Blood Cx, CT 490,668 6 112 111 <50 47 Azm, ETB 7
20 35, M Fever, abd pain, N/V, 
diarrhea
GI, abd LN Blood Cx, stool Cx, CT 48,053 2 364 3 70,324 13 Azm, ETB ---
Note: N/V, nausea and vomiting; abd, abdominal; LAN, lymphadenopathy; NS, night sweats; GI, gastrointestinal tract; LN, lymph node; Cx, culture; BMBx, bone marrow biopsy; Bx, biopsy; CT, CAT scan findings; Azm, azithromycin; ETB, 
ethambutol; Clm, clarithromycin; RIB, rifabutin.
a HIV quantitative PCR measured as copies/cc of plasma.
b CD4 count prior to the initiation of HAART.
c For responders, follow up = resolution of symptoms.
d Duration of time from the initiation of HAART to the development of IRIS symptoms.
Journal of Translational Medicine 2007, 5:50 http://www.translational-medicine.com/content/5/1/50avium complex was isolated from culture of the biopsy
specimen. He received azithromycin and ethambutol and
continued HAART. Clinical improvement was docu-
mented within one month and radiologic resolution at
one year. The CD4 cell count at that time was 229/mm3,
and the viral load was undetectable. Antimycobacterial
therapy was then discontinued.
Patient #3 (Responder; required prolonged corticosteroid
administration to manage inflammatory complications of
MAC IRIS involving the gastrointestinal tract): A 44-year-
old man was initially diagnosed with Pneumocystis pneu-
monia and HIV infection with a CD4 count of 69/mm3
and a viral load of 215,201 c/mL. HAART was initiated
and antimycobacterial therapy was begun 2 months after
an AFB isolator blood culture drawn at the time of his ini-
tial diagnosis because of ongoing fever yielded MAC. One
month later, fevers persisted, and MAC was isolated from
cultures of bone marrow. The antimycobacterial regimen
was intensified with rifabutin and ciprofloxacin in addi-
tion to azithromycin and ethambutol, and his fever
resolved. Two months later he developed recurrent fever
and abdominal pain. A repeat blood culture was positive
for MAC. An abdominal CT scan demonstrated multiple
enlarged intra-abdominal lymph nodes. His CD4 count
had increased to 199/mm3 with a viral load of 684 c/mL.
Because of significant abdominal pain associated with
MAC IRIS involving the gastrointestinal tract, oral corti-
costeroids were initiated. Seven days later, his symptoms
of abdominal pain completely resolved. Corticosteroids
were unable to be withdrawn because of persistent
abdominal pain and were therefore continued for 27
months. Antimycobacterial therapy was discontinued
after 3 years of treatment.
Non-responders
Four patients (numbers 17–20 in Table 2) had signs of
persistent, focal, end organ inflammation due to MAC
IRIS despite combination antimycobacterial treatment
(27 ± 33 months, range 7 months to 6.3 years) and con-
tinued HAART. Of these four non-responders, two died 7
months (patient #20) and 19 months (patient # 17) after
diagnosis. Patient # 20 developed rapid progression of
Kaposi sarcoma with the development of ascites that
became infected leading to overwhelming sepsis. Thus the
clinical impact of MAC recurrence could not be evaluated
in his case. A detailed description of patient #17 is out-
lined below. The mean CD4 cell count was 6/mm3 in this
non-responder group prior to treatment, 152/mm3 at IRIS
diagnosis, and 65/mm3 at the time of last follow up (Table
3). Abdominal lymph node was the most common site of
involvement in non-responders (4/4 [100%]); of the eight
patients with abdominal lymph node involvement, four
(50%) were responders. There was no major difference in
viral load responses between the 2 groups at the time of
IRIS diagnosis or IRIS follow up (Table 3).
Patient #17 (Non-responder; persistent MAC IRIS despite
treatment with poor immunologic response to HAART): A
46-year-old man was diagnosed with HIV infection in
1989 with a CD4 cell count of 4/mm3. Because of alcohol-
ism, he took antiretroviral therapy only intermittently. In
8/02 his CD4 cell count was 11/mm3 and his viral load
was 292,571 c/mL. A screening blood culture yielded
MAC, and he was started on ethambutol in addition to
azithromycin. In 9/02 he discontinued alcohol use and
began HAART with a regimen of didanosine, efavirenz,
and lopinavir/ritonavir. His CD4 cell count increased to
99/mm3 with a reduction in viral load to 3,636 c/mL. In
9/03, with a CD4 cell count of 72/mm3 and viral load of
1,991 c/mL, he was evaluated for severe right sided upper
abdominal pain. An abdominal CT scan revealed multiple
enlarged necrotic intra-abdominal lymph nodes (Figure
1). A percutaneous aspiration yielded 200 cc of purulent
material that demonstrated many AFB organisms on
smear, and culture grew MAC. The antimycobacterial reg-
imen was intensified with the addition of rifabutin and
ciprofloxacin. No information regarding macrolide sus-
ceptibility was available. Despite treatment, he developed
an enlarged supraclavicular lymph node abscess on this
regimen (Figure 2), which upon aspiration was found to
contain MAC. Amikacin and G-CSF were then added for
an additional six weeks. Because of persistent drainage
from the supraclavicular lymph node, which had eroded
to the surface despite percutaneous drainage, he also
began a 4-week course of linezolid. Despite HAART, his
CD4 count was 108/mm3 with a viral load < 50 c/mL. His
Abdominal CT demonstrating multiple abscessed intra-abdo inal lymph nodeFigure 1
Abdominal CT demonstrating multiple abscessed intra-
abdominal lymph nodes.Page 5 of 7
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Journal of Translational Medicine 2007, 5:50 http://www.translational-medicine.com/content/5/1/50intra-abdominal necrotic lymphadenopathy persisted
despite 15 months of treatment. He died 6 months later
from complications related to squamous cell carcinoma
of the rectum.
Discussion
The majority of patients with MAC IRIS (80%) had a com-
plete response to continuation of HAART and antimyco-
bacterial agents over a 36 month follow up period. Of
note, our study size was not large enough to permit a sta-
tistical analysis of features that may predict a favorable
outcome. Furthermore, there has been a decline in inci-
dence of MAC IRIS associated with the recent availability
of potent HIV agents effective in those with late stage or
highly resistant HIV infection. Because larger studies may
therefore not be forthcoming, there may be a utility in
making observations from our study about features that
may accompany favorable responses to MAC IRIS. For
example, we, as others, have noted a tendency of respond-
ers to maintain a more substantial HAART-associated
CD4 cell count increase than non-responders [11]. In
addition, responders tended to have involvement of
peripheral rather than abdominal lymph nodes as the site
of MAC IRIS. Although these observations suggest certain
factors may be important in the ultimate control of MAC
IRIS – CD4 responses and site of IRIS involvement, the
larger controlled studies that would be necessary to con-
firm these observations may not be accomplished within
the near future. Until then, the trends observed in our
report may be useful to clinicians currently managing
patients with MAC IRIS.
There has been insufficient information published in the
literature regarding the characteristics of patients who do
not respond to initial antimycobacterial therapy and who
develop persistent MAC IRIS disease. As is the case in our
study, the previous studies were unable to perform statis-
tical analyses of prognostic factors because of small sam-
ple sizes. Of the three papers that have reported three such
cases (without duplication of cases from the present
study), the average CD4 cell count prior to the initiation
of HAART was 96/mm3 with an increase to 213/mm3 at
the diagnosis of IRIS [5,7,9]. Few data are available regard-
ing the CD4 cell count at the time of relapse. One patient
had a CD4 cell count of 3/mm3, while the other had a
CD4 count of 382/mm3; both presented with lymphaden-
itis. No repeat CD4 cell count was reported for one patient
with chronic MAC involving breast tissue. These patients
developed MAC IRIS on average 5.6 months after starting
HAART. In addition, there is insufficient data regarding
whether a particular site of involvement, such as a periph-
eral lymph node, may have a more favorable outcome
because of a lower burden of mycobacterial organisms in
tissue, as well as being more amenable to surgical resec-
tion and medical management.
The lack of a standardized duration of antimycobacterial
therapy required to manage IRIS reflects the variation in
time in which a clinical and radiologic response may be
observed. In some patients with vigorous CD4 responses
to HAART, antimycobacterial agents may be withdrawn
after resolution of IRIS without the development of reac-
tivation. On the other hand, patients in our study with
MAC IRIS who did not experience a significant CD4
response to HAART, who did not have improvement in
symptoms, and/or who failed to eradicate MAC infection,
were managed with intensification of antimycobacterial
therapy and sometimes the addition of adjunctive ther-
apy. Of note, however, the strategy of antimycobacterial
therapy intensification, as well as the contribution made
by adjunctive agents in the management of MAC IRIS has
not been verified in controlled, prospective trials.
Our findings regarding the clinical features of MAC at the
time of diagnosis are consistent with prior reports. We and
others have found that IRIS is a focal inflammatory condi-
tion most often involving lymph nodes, liver or gastroin-
testinal tract. In addition, blood cultures rarely grow MAC
at the time of IRIS; rather, a biopsy of an involved focal
organ, such as lymph node, GI tract, or liver, is usually
required to establish a diagnosis [3]. Furthermore, as has
been shown in prior series, most (75%) but not all MAC
IRIS events occurred within 3 months of initiating HAART
[4,11-13]. Most patients in other series also had advanced
immune suppression at the initiation of HAART (CD4 cell
count 30/mm3 or less) and a CD4 cell count increase in
response to HAART at the time of IRIS diagnosis [4,11-
Left supraclavicular abscessed lymph nodeFigure 2
Left supraclavicular abscessed lymph node. Written informed 
consent was obtained for use of this image from the patient's 
relative.Page 6 of 7
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13]. Finally, corticosteroids are required to manage symp-
toms in some, but not all patients.
In conclusion, the majority of patients with MAC IRIS
experience favorable responses to long-term antimycobac-
terial therapy. Patients who have an adequate CD4
response to HAART may have antimycobacterial treat-
ment safely withdrawn following resolution of focal
involvement. However, neither the present study nor pre-
vious reports have had ample numbers of patients to per-
mit statistical analyses of factors predicting a favorable
outcome. Furthermore, the incidence of MAC IRIS may be
declining with the development of newer agents to man-
age HIV. Nonetheless, the observations of the current
study – that adequate immunologic responses to HAART
and peripheral lymph node location of MAC IRIS may be
associated with favorable outcomes, may be useful for
physicians managing patients with AIDS who develop
MAC IRIS.
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